Last reviewed · How we verify
levofloxacin-based triple therapy for 10 days
At a glance
| Generic name | levofloxacin-based triple therapy for 10 days |
|---|---|
| Also known as | Takepron, Cravit, Amoxicillin |
| Sponsor | National Taiwan University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection (PHASE4)
- Eradication of H. Pylori Infection With Moxifloxacin (PHASE3)
- Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication. (PHASE4)
- Antimicrobial Susceptibility Testing Guided Therapy Versus Empirical Therapy for the First-line Helicobacter Pylori Eradication. (PHASE4)
- Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico. (PHASE3)
- Efficacy and Safety of Basic Triple Therapy Including Ilaprazole on the First Line Eradication Treatment of H.Pylori
- Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy (PHASE4)
- Community-based Helicobacter Pylori Eradication (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: